Tyler Van Buren
Stock Analyst at TD Cowen
(2.26)
# 2,518
Out of 4,759 analysts
57
Total ratings
43.48%
Success rate
-1.85%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $26.72 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $11.38 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $29.86 | +151.17% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $16.55 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $10.46 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $35.61 | +68.49% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $5.36 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $18.40 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $707.51 | +69.61% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $23.18 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $23.80 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $117.41 | -27.60% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $45.53 | -34.11% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.96 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.49 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $70.74 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $36.14 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.65 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $18.09 | +65.84% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $31.57 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.01 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $29.80 | +134.90% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.82 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.28 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.94 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.64 | +2,948.78% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $12.94 | +6,661.98% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $1.15 | +3,378.26% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $13.86 | +188.60% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $9.53 | +214.80% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.44 | +13,561.20% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.62 | +2,986.42% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.21 | +2,379.34% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $4.58 | +4,266.81% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.66 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.36 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $26.72
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.38
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $29.86
Upside: +151.17%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $16.55
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $10.46
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $35.61
Upside: +68.49%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $5.36
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $18.40
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $707.51
Upside: +69.61%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $23.18
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $23.80
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $117.41
Upside: -27.60%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $45.53
Upside: -34.11%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.96
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.49
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $70.74
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $36.14
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.65
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $18.09
Upside: +65.84%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $31.57
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.01
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $29.80
Upside: +134.90%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.82
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $18.28
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.94
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.64
Upside: +2,948.78%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $12.94
Upside: +6,661.98%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $1.15
Upside: +3,378.26%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $13.86
Upside: +188.60%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $9.53
Upside: +214.80%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.44
Upside: +13,561.20%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.62
Upside: +2,986.42%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.21
Upside: +2,379.34%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $4.58
Upside: +4,266.81%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $7.66
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $15.36
Upside: -